Chapter

Treatment: where are we going?

Albrecht Ziegler

in Migraine: A Spectrum of Ideas

Published in print March 1990 | ISBN: 9780192618108
Published online March 2012 | e-ISBN: 9780191724305 | DOI: http://dx.doi.org/10.1093/acprof:oso/9780192618108.003.0025
Treatment: where are we going?

Show Summary Details

Preview

This chapter deals with problems that lie on the borderline between the pathophysiology, the pharmacotherapy, and the pharmacology of migraine. Our hopes must centre on this border, because an intimate and reliable knowledge of these fields will offer a clue towards an optimal therapeutic strategy. Researchers should concentrate on the drugs that have been developed as alternatives to ergotamine. It is to be hoped that these new drugs will be free of the inherent drawback of ergotamine — its deleterious side-effects when given too frequently. Satisfying results in clinical practice could render the prophylactic treatment of migraine superfluous. It could be a real advantage to avoiding prophylactic treatment, which always has to meet the high standards required of any long-term medication.

Keywords: therapeutic strategy; migraine pharmacology; ergotamine; prophylactic treatment; long-term medication; side-effects

Chapter.  4926 words. 

Subjects: Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.